NANTES, FRANCE--(Marketwire - September 28, 2010) -
VIVALIS (NYSE Euronext: VLS), a
biopharmaceutical company, announced today that Mymetics Corporation
(NASDAQ:
MYMX), a Swiss company that develops a new generation of mucosal-
and virosome-based vaccines, has signed a research license agreement to
evaluate the replication of an undisclosed virus in VIVALIS' EB66® cell
line for the manufacturing of human vaccines developed by Mymetics.
Terms of the agreement were not disclosed.
"We are very pleased to have another organization evaluating our EB66®
cell line. This agreement brings the number of worldwide, new research and
commercial licenses to the EB66® cell line up to four in 2010. We also
continue to engage in advanced discussions with many organizations, both
for vaccine and protein production, and are confident that 2010 will
continue to reinforce our position as a provider of novel cell-based
technologies to the biopharmaceutical industry," said Franck Grimaud, CEO,
and Majid Mehtali, CSO, co-managers of VIVALIS.
**********************
Next Financial Press Release
October 20, 2010: Third Quarter Revenues for 2010 (after NYSE Euronext
market close)
About The EB66® Cell Line
The EB66® cell line, derived from avian embryonic stem cells, presents
unique industrial and regulatory characteristics, such as long-term genetic
stability, immortality and cell growth up to high cell densities in
suspension using serum-free media ( > 40 million cells/mL).
EB66® cells replicate a wide range of human and animal viruses and are
currently used for the production of investigational viral vaccines by many
major vaccine developers.
A Biologics Master File (BMF) for the EB66® cell line with the U.S. Food
and Drug Administration (FDA) was filed on June 27, 2008 and is updated
annually.
EB66® cells are also easily engineered to express recombinant proteins of
interest ( > 1.0 g/l). Monoclonal antibodies produced in EB66® cells
have a human-like glycosylation profile with the additional benefits of
reduced fucose content, naturally. This latter characteristic provides
increased cytotoxic activity (ADCC) to antibodies, which may be useful in
the treatment of cancer and infectious disease.
About VIVALIS (www.vivalis.com)
VIVALIS (Euronext: VLS) is a biopharmaceutical company that provides
innovative cell-based solutions to the pharmaceutical industry for the
manufacture of vaccines and proteins, and develops drugs for the prevention
and treatment of unmet medical needs. VIVALIS' expertise and intellectual
property are leveraged in three main areas:
EB66® Cell Line
VIVALIS offers research and commercial licenses for its EB66® cell line,
derived from duck embryonic stem cells, to pharmaceutical and biotechnology
companies for the production of therapeutic and prophylactic viral
vaccines, virosomes, VLP's, and recombinant proteins (with a focus on
monoclonal antibodies having enhanced cytotoxic activity). Through these
programs VIVALIS receives upfront, clinical, and milestone payments along
with royalties on licensees net sales.
Humalex® Human Antibody Discovery Platform
Customized solutions for the discovery, development, and production of
fully human monoclonal antibodies is now offered by VIVALIS. Through these
programs VIVALIS receives upfront, clinical, and milestone payments along
with royalties on licensees net sales.
3D-Screen Platform
VIVALIS performs discovery and early stage development of small molecules
identified with VIVALIS' proprietary 3D-Screen platform, which identifies
target protein conformational modulators. VIVALIS is also building a
portfolio of proprietary products for the treatment of hepatitis-C
infection using this platform.
Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud Group
(ca. 1,500 employees), a world-wide leader in animal genetic selection.
VIVALIS has established more than 30 partnerships and licenses with world
leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck,
CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of
both the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.
+-------------------------+-+
|VIVALIS | |
+-------------------------+-+
|Listed on Euronext Paris | |
|– Compartment C of NYSE | |
|Euronext | |
+-------------------------+-+
|Reuters: VLS.PA – | |
|Bloomberg: VLS FP | |
+-------------------------+-+
|Included in NYSE | |
|Euronext’s SBF 250, CAC | |
|Small 90 and Next Biotech| |
|indices | |
+-------------------------+-+
+-------------------------+-+
This document contains forward-looking statements and comments on the
company's objectives and strategies. No guarantee can be given to any of
the events anticipated by the forward-looking statements contained in this
document, which are subject to inherent risks, including risk factors
described in the company's document de référence, changes in
economic conditions, the financial markets or the markets in which the
company operates.
